NYSE:VOR

Vor Biopharma Competitors

$30.10
-1.40 (-4.44 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.33
Now: $30.10
$31.91
50-Day Range
$29.14
MA: $38.62
$54.08
52-Week Range
$25.32
Now: $30.10
$63.62
Volume151,379 shs
Average Volume289,757 shs
Market Capitalization$1.12 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Vor Biopharma (NYSE:VOR) Vs. SEER, NUVB, IBRX, IMCR, BCAB, and CGEM

Should you be buying VOR stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Vor Biopharma, including Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), Immunocore (IMCR), BioAtla (BCAB), and Cullinan Oncology (CGEM).

Vor Biopharma (NYSE:VOR) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vor Biopharma and Seer, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vor Biopharma10402.60
Seer02202.50

Vor Biopharma currently has a consensus target price of $48.20, suggesting a potential upside of 60.13%. Seer has a consensus target price of $68.00, suggesting a potential upside of 33.73%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Seer.

Earnings and Valuation

This table compares Vor Biopharma and Seer's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vor BiopharmaN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Profitability

This table compares Vor Biopharma and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vor BiopharmaN/AN/AN/A
SeerN/AN/AN/A

Summary

Vor Biopharma beats Seer on 3 of the 3 factors compared between the two stocks.

Vor Biopharma (NYSE:VOR) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vor Biopharma and Nuvation Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vor Biopharma10402.60
Nuvation Bio00603.00

Vor Biopharma currently has a consensus target price of $48.20, suggesting a potential upside of 60.13%. Nuvation Bio has a consensus target price of $17.40, suggesting a potential upside of 73.48%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Vor Biopharma.

Earnings and Valuation

This table compares Vor Biopharma and Nuvation Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vor BiopharmaN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Profitability

This table compares Vor Biopharma and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vor BiopharmaN/AN/AN/A
Nuvation BioN/AN/AN/A

Summary

Nuvation Bio beats Vor Biopharma on 3 of the 3 factors compared between the two stocks.

Vor Biopharma (NYSE:VOR) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vor Biopharma and ImmunityBio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vor Biopharma10402.60
ImmunityBio00103.00

Vor Biopharma currently has a consensus target price of $48.20, suggesting a potential upside of 60.13%. ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 43.84%. Given Vor Biopharma's higher probable upside, analysts plainly believe Vor Biopharma is more favorable than ImmunityBio.

Earnings and Valuation

This table compares Vor Biopharma and ImmunityBio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vor BiopharmaN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Profitability

This table compares Vor Biopharma and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vor BiopharmaN/AN/AN/A
ImmunityBioN/AN/AN/A

Summary

Vor Biopharma beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Earnings & Valuation

This table compares Immunocore and Vor Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
Vor BiopharmaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and Vor Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Vor Biopharma10402.60

Immunocore currently has a consensus price target of $54.3333, suggesting a potential upside of 42.05%. Vor Biopharma has a consensus price target of $48.20, suggesting a potential upside of 60.13%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Immunocore.

Profitability

This table compares Immunocore and Vor Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
Vor BiopharmaN/AN/AN/A

Summary

Vor Biopharma beats Immunocore on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares BioAtla and Vor Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Vor BiopharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for BioAtla and Vor Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Vor Biopharma10402.60

BioAtla presently has a consensus price target of $58.00, indicating a potential upside of 21.49%. Vor Biopharma has a consensus price target of $48.20, indicating a potential upside of 60.13%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than BioAtla.

Profitability

This table compares BioAtla and Vor Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Vor BiopharmaN/AN/AN/A

Cullinan Oncology (NASDAQ:CGEM) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares Cullinan Oncology and Vor Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
Vor BiopharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Cullinan Oncology and Vor Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology01302.75
Vor Biopharma10402.60

Cullinan Oncology presently has a consensus price target of $48.25, indicating a potential upside of 37.07%. Vor Biopharma has a consensus price target of $48.20, indicating a potential upside of 60.13%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Cullinan Oncology.

Profitability

This table compares Cullinan Oncology and Vor Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
Vor BiopharmaN/AN/AN/A

Summary

Vor Biopharma beats Cullinan Oncology on 2 of the 3 factors compared between the two stocks.


Vor Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SEER
Seer
1.2$50.85-4.2%$3.10 billionN/A0.00Increase in Short Interest
Gap Down
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$10.03-0.4%$2.18 billionN/A0.00Analyst Report
Insider Buying
IBRX
ImmunityBio
1.7$17.38-0.7%$1.90 billionN/A0.00Gap Up
Immunocore logo
IMCR
Immunocore
1.3$38.25-3.0%$1.65 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.5$47.74-0.4%$1.61 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.20-2.0%$1.53 billionN/A0.00Gap Down
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$37.64-3.5%$1.31 billionN/A0.00Analyst Report
Gap Down
KNTE
Kinnate Biopharma
1.7$29.64-5.2%$1.29 billionN/A0.00Increase in Short Interest
Gap Down
EWTX
Cricut
0.3$27.08-3.1%$1.29 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
1.9$29.03-6.8%$1.29 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
Gap Down
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.27-0.2%$963.96 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$27.92-0.5%$888.97 millionN/A0.00News Coverage
Gap Down
FDMT
4D Molecular Therapeutics
1.3$33.20-9.3%$886.24 millionN/A0.00Increase in Short Interest
News Coverage
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.90-6.9%$845.76 millionN/A0.00
Pharming Group logo
PHAR
Pharming Group
0.0$13.07-3.9%$834.94 millionN/A0.00Decrease in Short Interest
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.36-8.8%$812.29 millionN/A0.00Analyst Report
Gap Down
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.29-3.4%$782.36 millionN/A0.00Analyst Report
Increase in Short Interest
Gap Down
FNCH
Finch Therapeutics Group
2.0$15.99-3.1%$753.85 millionN/A0.00Analyst Report
Analyst Revision
Gap Down
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$15.15-3.6%$615.42 millionN/A0.00
SGTX
Sigilon Therapeutics
1.4$17.04-8.2%$536.64 millionN/A0.00Increase in Short Interest
Gap Down
Inventiva logo
IVA
Inventiva
1.4$13.34-0.5%$515.32 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.24-2.0%$483.31 millionN/A0.00Analyst Report
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.51-2.1%$461.76 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$17.91-1.1%$449.99 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.12-5.8%$431.90 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$18.74-12.1%$426.49 millionN/A0.00News Coverage
Gap Down
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$14.07-5.6%$414.84 millionN/A0.00
PRTG
Portage Biotech
0.0$26.99-7.6%$326.12 millionN/A0.00High Trading Volume
News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.34-4.1%$292.09 millionN/A-2.84Gap Down
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.50-16.2%$276.04 millionN/A-2.57Unusual Options Activity
News Coverage
Gap Down
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.89-8.7%$246.28 millionN/A0.00Gap Down
LBPH
Longboard Pharmaceuticals
1.9$11.63-7.0%$196.75 millionN/A0.00Analyst Report
Quiet Period Expiration
Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$10.10-3.4%$193.10 millionN/A0.00Increase in Short Interest
Gap Up
GANX
Gain Therapeutics
1.7$14.50-2.8%$164.30 millionN/A0.00Analyst Revision
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.55-0.1%$149.71 millionN/A0.00
VINC
Vincerx Pharma
1.0$17.60-4.0%$144.41 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.52-18.4%$125.18 millionN/A0.00Gap Up
LGVN
Longeveron
0.3$6.52-9.5%$123.60 millionN/A0.00News Coverage
Gap Down
UPC
Universe Pharmaceuticals
0.0$3.87-6.5%$84.17 millionN/A0.00Gap Up
VRDN
Viridian Therapeutics
1.7$14.76-2.8%$57.68 millionN/A0.00Decrease in Short Interest
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.24-3.4%$52.67 millionN/A0.00Gap Down
VIRI
Virios Therapeutics
1.3$5.58-1.1%$46.48 millionN/A0.00News Coverage
Gap Down
VIRX
Viracta Therapeutics
1.7$8.00-0.4%$41.39 millionN/A0.00
VYNT
Vyant Bio
0.0$3.65-0.3%$40.18 millionN/A0.00News Coverage
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.20-6.3%$37.69 millionN/A0.00News Coverage
VLON
Vallon Pharmaceuticals
0.3$4.55-2.0%$30.99 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$4.36-3.2%$23.39 millionN/A0.00Gap Up
CMMB
Chemomab Therapeutics
0.0$27.26-23.2%$12.65 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.26-0.6%$2.52 millionN/A0.00News Coverage
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.57-4.7%$0.00N/A0.00Gap Up
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.